Evidence map›Paper›PMID 32954261›Full record

ArticleBrain communications2019

Alessandro Biffi, Meredith P Murphy, Patryk Kubiszewski, Christina Kourkoulis, Kristin Schwab, Mahmut Edip Gurol, Steven M Greenberg, Anand Viswanathan, Christopher D Anderson, Jonathan Rosand

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Alessandro BiffiHenry and Allison McCance Center for Brain Health, MGH, Boston, MA, USA.
Meredith P MurphyHenry and Allison McCance Center for Brain Health, MGH, Boston, MA, USA.
Patryk KubiszewskiHenry and Allison McCance Center for Brain Health, MGH, Boston, MA, USA.
Christina KourkoulisCenter for Genomic Medicine, Massachusetts General Hospital (MGH), Boston, MA, USA.
Kristin SchwabHemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, MGH, Boston, MA, USA.
Mahmut Edip GurolHemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, MGH, Boston, MA, USA.
Steven M GreenbergHemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, MGH, Boston, MA, USA.
Anand ViswanathanHemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, MGH, Boston, MA, USA.
Christopher D AndersonHemorrhagic Stroke Research Program, J. Philip Kistler Stroke Research Center, MGH, Boston, MA, USA.
Jonathan RosandHenry and Allison McCance Center for Brain Health, MGH, Boston, MA, USA.
Massachusetts General Hospital · USBroad Institute · USMGH Institute of Health Professions · US

Funding

Center for Common Disease GeneticsUM1HG008895 · NHGRI · BROAD INSTITUTE, INC. · PI DALY, MARK JOSEPH, GABRIEL, STACEY · 2016 to 2020
$111.2M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BETENSKY, REBECCA A. · 1985 to 2018
$42.1M
Genetic&Environment Risk Factors for Hemorrhagic StrokeR01NS036695 · NINDS · UNIVERSITY OF CINCINNATI · PI WOO, DANIEL · 1997 to 2012
$14.1M
Recurrent Hemorrhagic Stroke in Minority PopulationsR01NS093870 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI JONATHAN ROSAND, Amytis Towfighi · 2016 to 2026
$12.3M
Vascular Dysfunction in Cerebral Amyloid AngiopathyR01AG026484 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBERG, STEVEN M · 2005 to 2019
$7.5M
Vascular Pathology in Early and Asymptomatic Cerebral Amyloid AngiopathyR01AG047975 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VISWANATHAN, ANAND · 2014 to 2025
$7.5M
Sequencing Annotation and Functional Analysis in Risk of Intracerebral HemorrhageR01NS103924 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDERSON, CHRISTOPHER DAVID · 2018 to 2022
$3.4M
Platform for Accelerating Genetic Discovery for Cerebrovascular DiseaseR24NS092983 · NINDS · BROAD INSTITUTE, INC. · PI ROSAND, JONATHAN · 2015 to 2018
$1.2M
Apathy and Depression following Intracerebral HemorrhageK23NS100816 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BIFFI, ALESSANDRO · 2017 to 2021
$1.0M
Genetic Analyses of Lipids in Cerebral Hemorrhage and Small Vessel DiseaseK23NS086873 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDERSON, CHRISTOPHER DAVID · 2014 to 2018
$951k
Effect of White Matter Disease on Gait and Balance in Cerebral Amyloid AngiopathyK23AG028726 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VISWANATHAN, ANAND · 2010 to 2014
$823k
American Heart Association-American Stroke Association 18SFRN34110082NHGRI NIH HHS UM1 HG008895NIA NIH HHS K23 AG028726NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG026484NIA NIH HHS R01 AG047975NINDS NIH HHS K23 NS086873NINDS NIH HHS K23 NS100816NINDS NIH HHS R01 NS036695NINDS NIH HHS R01 NS093870NINDS NIH HHS R01 NS103924NINDS NIH HHS R24 NS092983
6 · The paper itself

Abstract

Intracerebral haemorrhage in the elderly is a severe manifestation of common forms of cerebral small vessel disease. Nearly 60% of intracerebral haemorrhage survivors will develop clinical manifestations of small vessel disease progression including recurrent haemorrhage, ischaemic stroke, dementia, late-life depression and gait impairment within 5 years. Blood pressure measurements following intracerebral haemorrhage are strongly associated with this risk. However, aggressive blood pressure lowering in the elderly carries substantial risks. In order to determine whether there might be an opportunity to select individuals at the highest risk for small vessel disease progression for aggressive blood pressure reduction, we investigated whether

Indexed as

APOEhypertensionintracerebral haemorrhage

Identifiers

PMID32954261
PMCPMC7425529
OpenAlexW2974809172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.